Adverum Biotechnologies Stock Fundamentals
| ADVM Stock | USD 9.30 0.31 3.23% |
Adverum Biotechnologies fundamentals help investors to digest information that contributes to Adverum Biotechnologies' financial success or failures. It also enables traders to predict the movement of Adverum Stock. The fundamental analysis module provides a way to measure Adverum Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adverum Biotechnologies stock.
At this time, Adverum Biotechnologies' Depreciation And Amortization is very stable compared to the past year. As of the 12th of May 2024, Total Other Income Expense Net is likely to grow to about 5.8 M, though Interest Expense is likely to grow to (2.3 M). Adverum | Select Account or Indicator |
Adverum Biotechnologies Company Shares Outstanding Analysis
Adverum Biotechnologies' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Adverum Biotechnologies Shares Outstanding | 20.76 M |
Most of Adverum Biotechnologies' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adverum Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adverum Shares Outstanding Historical Pattern
Today, most investors in Adverum Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adverum Biotechnologies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Adverum Biotechnologies shares outstanding as a starting point in their analysis.
Adverum Biotechnologies Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Adverum Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Adverum Biotechnologies has 20.76 M of shares currently outstending. This is 88.5% lower than that of the Biotechnology sector and 80.57% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 96.37% higher than that of the company.
Adverum Biotechnologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adverum Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adverum Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adverum Biotechnologies competition to find correlations between indicators driving Adverum Biotechnologies's intrinsic value. More Info.Adverum Biotechnologies is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, Adverum Biotechnologies' Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Adverum Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Adverum Biotechnologies' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Adverum Biotechnologies' earnings, one of the primary drivers of an investment's value.Adverum Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adverum Biotechnologies' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adverum Biotechnologies could also be used in its relative valuation, which is a method of valuing Adverum Biotechnologies by comparing valuation metrics of similar companies.Adverum Biotechnologies is currently under evaluation in shares outstanding category among related companies.
Adverum Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (34.38) % | ||||
| Current Valuation | 171.53 M | ||||
| Shares Outstanding | 20.76 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 88.49 % | ||||
| Number Of Shares Shorted | 1.2 M | ||||
| Price To Earning | (2.10) X | ||||
| Price To Book | 2.92 X | ||||
| Price To Sales | 67.63 X | ||||
| Revenue | 3.6 M | ||||
| Gross Profit | (81.68 M) | ||||
| EBITDA | (118.15 M) | ||||
| Net Income | (117.17 M) | ||||
| Cash And Equivalents | 235.84 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 75.04 M | ||||
| Debt To Equity | 0.43 % | ||||
| Current Ratio | 8.03 X | ||||
| Book Value Per Share | 8.23 X | ||||
| Cash Flow From Operations | (91.32 M) | ||||
| Short Ratio | 4.07 X | ||||
| Earnings Per Share | (11.60) X | ||||
| Target Price | 35.33 | ||||
| Number Of Employees | 121 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 193.04 M | ||||
| Total Asset | 173.01 M | ||||
| Retained Earnings | (919.78 M) | ||||
| Working Capital | 77.86 M | ||||
| Current Asset | 260.99 M | ||||
| Current Liabilities | 6.57 M | ||||
| Net Asset | 173.01 M |
About Adverum Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adverum Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adverum Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adverum Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 116.2 K | 110.3 K | |
| Total Revenue | 4.1 M | 2.8 M | |
| Cost Of Revenue | 5.6 M | 5.4 M | |
| Stock Based Compensation To Revenue | 4.39 | 7.46 | |
| Sales General And Administrative To Revenue | 12.48 | 17.94 | |
| Research And Ddevelopement To Revenue | 19.37 | 28.66 | |
| Capex To Revenue | (0.26) | (0.27) | |
| Revenue Per Share | 0.32 | 0.34 | |
| Ebit Per Revenue | (39.54) | (41.52) |
Pair Trading with Adverum Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adverum Stock
| 0.81 | EGRX | Eagle Pharmaceuticals | PairCorr |
Moving against Adverum Stock
| 0.83 | VRCA | Verrica Pharmaceuticals Earnings Call Tomorrow | PairCorr |
| 0.75 | JANX | Janux Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.71 | YCBD | cbdMD Inc Earnings Call Tomorrow | PairCorr |
| 0.62 | ELYM | Eliem Therapeutics Earnings Call Tomorrow | PairCorr |
| 0.45 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.
The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Adverum Biotechnologies Piotroski F Score and Adverum Biotechnologies Altman Z Score analysis. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Adverum Stock analysis
When running Adverum Biotechnologies' price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.60) | Revenue Per Share 0.357 | Quarterly Revenue Growth (0.70) | Return On Assets (0.32) | Return On Equity (0.88) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.